IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

In re application of:

Alvaro et al.

Intl. Serial No.:

PCT/GB03/00499

Group Art Unit: To Be Assigned

Intl. File Date:

February 5, 2003

Examiner:

To Be Assigned

For:

Piperidylcarboxamide Derivatives And Their Use In The Treatment Of Tachykinm-

Mediated Diseases

M/S PCT/EO/DO/US Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[] [X]	Copies of the references are enclosed: Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No. PCT/GB03/00499 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
	[Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.
		22 22 22

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure [] Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure [] Statement. 37 CFR 1.97(d)(ii).
- The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith. []
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan

Registration No. 38,181

Date: 22 Jan 204 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

10/502266

DT15 Rec'd PCT/PTO 22 JULE 2004

FORM PEO	1 4 4 0	 		AMEGRATINA DOCKET NO.						
FORM PTO		MECI ACUBE CT	'A TENTENT	ATTORNEY DOCKET NO. PI4749USW		INTL. SERIAL NO. PCT/GB03/00499				
INFURIVIA	HONI	DISCLOSURE ST	AIEWENI	APPLICANT: Alvaro et al.						
				INTL. FILING DATE: GROUP						
				February 5, 2003						
U.S. PATENT DOCUMENTS										
Examiner Initials		Patent	Issue Date		Name	Class	Subclass	Filing Date If Appropriate		
Tinuais		Number								
				ļ			<u> </u>			
			ļ	<u> </u>			· · · · · · · · · · · · · · · · · · ·			
				ļ		ļ	<u> </u>			
				 	-					
			 							
			ļ	 		<u> </u>				
				 						
		<u> </u>		ontinue on r	la de	L		L		
Continue on page FOREIGN PATENT DOCUMENTS										
		Document	Publication	I	DOCUMENTS			Translation		
		Number	Date		Country	Class	Subclass	Yes No		
		WO 02/32867	Apr 25, 2002	WIPO						
		WO 97/16440	May 9, 1997	WIPO						
		WO 97/24324	July 10, 1997	WIPO						
		EP 0532456	Mar 17, 1993	Europe						
		WO 99/37304	July 29, 1999	WIPO						
					<u></u>					
			ļ	ļ						
				ļ						
			l	1				<u> </u>		
		OWNED BOOK	CENTES CITAL	ontinue on p	age Title, Journal-Date, P	N	or Etc.)			
		OTHER DOCUM	MEN 15 (Includi	ng Author,	I itie, Journai-Date, P	age Numb	er, Etc.)	-		
										
	-	*****								
				<u> </u>						
							-			
**										
		,								
				Continue on	page	DAME C	ONGIDERER			
EXAMINER DATE CONSIDERED										
EXAMINER	: Initia	l if citation consid	ered, whether or i	not citation i	s in conformance with I	MPEP § 60	9; Draw line thre	ough citation		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.										